DIEGO SALA TRULL

Dr. DIEGO SALA TRULL

Urgencias, Hospital Universitario de La Plana, Villareal, Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
GBGema Badenes-Marques
Gema Badenes-Marques
MFMARIA GIL FORTUÑO
MARIA GIL FORTUÑO
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Background: In March 2020, a COVID-19 outbreak linked to mass gathering dinners at the Falles Festival in Borriana, Spain, resulted in an estimated attack rate of 42.6% among attendees. Methods: In June 2022, we conducted a cross-sectional follow-up study of 473 adults aged 18 to 64 who attended the dinners at the Falles Festival in 2020, examining the cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, infection records, and vaccinations from a population-based vaccine registry. Blood samples were analyzed for SARS-CoV-2 antibodies and cellular immunity. We employed a doubly robust inverse-probability weighting analysis to estimate the booster vaccine dose’s impact on long COVID prevalence and symptom count. Results: A total of 28.1% of participants met the WHO criteria for long COVID, with older individuals showing higher rates. Long COVID diagnosis was less likely with factors including O blood group, higher occupational status, physical activity, three vaccine doses, strong SARS-CoV-2-S-reactive IFNγ-producing-CD8+ response, and infection during the Omicron period. Increased age, high or low social activity, underlying health conditions, a severe initial COVID episode, and reinfection were associated with higher long COVID likelihood. A booster dose, compared to one or two doses, reduced long COVID risk by 74% (95% CI: 56% to 92%) and symptom count by 55% (95% CI: 32% to 79%). Conclusion: Long COVID was prevalent in a significant portion of those who contracted COVID-19, underscoring the need for sustained follow-up and therapeutic strategies. Vaccinations, notably the booster dose, had a substantial beneficial effect on long-term infection outcomes, affirming the vaccination’s role in mitigating SARS-CoV-2 infection consequences.

28 January 2023 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
OGOlga Guerra-Murcia
Olga Guerra-Murcia
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Our objective was to estimate the incidence of COVID-19 and the ABO blood Groups in the mass-gathering events (MGEs) during the Falles Festival in Borriana (Spain) from 6–10 March 2020. We conducted a population-based retrospective cohort study and measured anti-SARS-CoV-2 antibodies and the ABO of participants. We performed laboratory COVID-19 tests and obtained the ABO in 775 subjects (72.8% of the original exposed cohort): O-group (45.2%), A-group (43.1%), B-group (8.5%) and AB-group (3.4%). Adjusted for confounding factors, including COVID-19 exposure during the MGEs, attack rates of COVID-19 for each ABO group were 55.4%, 59.6%, 60.2%, and 63.7%. The adjusted relative risks were for O-group 0.93 (95% Confidence Interval [CI] 0.83–1.04), for A-group 1.06 (95% CI 0.94–1.18), for B-group 1.04 (95%CI 0.88–1.24), and for AB-group 1.11 (95% CI 0.81–1.51) with no significant differences. Conclusions: Our results suggest no effect of ABO on COVID-19 incidence. We observed weak but not significant protection of the O-group and not a significantly greater infection risk for the remaining groups compared with the O-group. More studies are needed to resolve the controversies regarding the association between ABO and COVID-19.

1 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
GBGemma Badenes-Marques
Gemma Badenes-Marques
MFMARIA GIL FORTUÑO
MARIA GIL FORTUÑO
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Background: In March 2020, a COVID-19 outbreak associated with the Falles Festival in Borriana, Spain, led to significant infections. Methods: In June 2022, we conducted a cross-sectional follow-up study of 473 socially engaged adults aged 18 to 64, examining the cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, infection records, and vaccinations from a population-based vaccine registry. Blood samples were analyzed for SARS-CoV-2 antibodies and cellular immunity. We employed a doubly robust inverse weighted probability analysis to estimate the booster vaccine dose's impact on long COVID prevalence and symptom count. Results: 28.1% of participants met the WHO criteria for long COVID, with older individuals showing higher rates. Not complying with long COVID criteria associated with factors including O blood group, higher occupational status, physical activity, three vaccine doses, strong SARS-CoV-2-S-reactive IFNγ‐producing‐CD8+ response, and infection during the Omicron period. Conversely, increased age, high or low social activity, underlying health conditions, a severe initial COVID episode, and reinfection associated with higher long COVID likelihood. A booster dose, compared to one or two doses, reduced long COVID risk by 74% (95% CI: 56.4% to 91.7%) and symptom count by 55.2% (95% CI: 31.6% to 78.7%). Conclusion: Long COVID was prevalent in a significant portion of those who contracted COVID-19, underscoring the need for sustained follow-up and therapeutic strategies. Vaccinations, notably the booster dose, had a substantial beneficial effect on long-term infection outcomes, affirming the vaccination’s role in mitigating SARS-CoV-2 infection consequences.

10 April 2024 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
LLLORNA GOMEZ LANAS
LORNA GOMEZ LANAS
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Our goal was to determine the cellular immune response (CIR) in a sample of the Borriana COVID-19 cohort (Spain) to identify associated factors and their relationship with infection, reinfection and sequelae. We conducted a nested case–control study using a randomly selected sample of 225 individuals aged 18 and older, including 36 individuals naïve to the SARS-CoV-2 infection and 189 infected patients. We employed flow-cytometry–based immunoassays for intracellular cytokine staining, using Wuhan and BA.2 antigens, and chemiluminescence microparticle immunoassay to detect SARS-CoV-2 antibodies. Logistic regression models were applied. A total of 215 (95.6%) participants exhibited T-cell response (TCR) to at least one antigen. Positive responses of CD4+ and CD8+ T cells were 89.8% and 85.3%, respectively. No difference in CIR was found between naïve and infected patients. Patients who experienced sequelae exhibited a higher CIR than those without. A positive correlation was observed between TCR and anti-spike IgG levels. Factors positively associated with the TCR included blood group A, number of SARS-CoV-2 vaccine doses received, and anti-N IgM; factors inversely related were the time elapsed since the last vaccine dose or infection, and blood group B. These findings contribute valuable insights into the nuanced immune landscape shaped by SARS-CoV-2 infection and vaccination.

Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
LLLaura López-Diago
Laura López-Diago
IGIsabel Aleixandre Górriz
Isabel Aleixandre Górriz
OPOscar Pérez-Olaso
Oscar Pérez-Olaso
DTDIEGO SALA TRULL
DIEGO SALA TRULL
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been studied little. Our aim was to quantify the risk of reinfections considering VitD status before reinfection. Methods: We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020–2023, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed. Results: Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in our study, with an average age of 38.8 years; 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were 0.50 for a deficient status (<20 ng/mL), 0.50 for an insufficient status (20–29 ng/mL), and 0.37 for a sufficient status (≥30 ng/mL). Compared with a sufficient VitD status, adjusted hazard ratios were 1.79 (95% confidence interval [CI] 0.89–3.59) for a deficient status and 1.59 (95% CI 1.06–2.38) for an insufficient status with a significant inverse dose–response (p = 0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections. Conclusions: These results suggest that a VitD status lower than 30 ng/mL showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.

9 August 2024 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
DTDIEGO SALA TRULL
DIEGO SALA TRULL
ARAlba Del Río
Alba Del Río
Manuel Sánchez-UrbanoManuel Sánchez-Urbano
Manuel Sánchez-Urbano
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Determining the number of cases of an epidemic is the first function of epidemiological surveillance. An important underreporting of cases was observed in many locations during the first wave of the COVID-19 pandemic. To estimate this underreporting in the COVID-19 outbreak of Borriana (Valencia Community, Spain) in March 2020, a cross-sectional study was performed in June 2020 querying the public health register. Logistic regression models were used. Of a total of 468 symptomatic COVID-19 cases diagnosed in the outbreak through anti-SARS-CoV-2 serology, 36 cases were reported (7.7%), resulting in an underreporting proportion of 92.3% (95% confidence interval [CI], 89.5–94.6%), with 13 unreported cases for every reported case. Only positive SARS-CoV-2 polymerase chain reaction cases were predominantly reported due to a limited testing capacity and following a national protocol. Significant factors associated with underreporting included no medical assistance for COVID-19 disease, with an adjusted odds ratio [aOR] of 10.83 (95% CI 2.49–47.11); no chronic illness, aOR = 2.81 (95% CI 1.28–6.17); middle and lower social classes, aOR = 3.12 (95% CI 1.42–6.85); younger age, aOR = 0.97 (95% CI 0.94–0.99); and a shorter duration of illness, aOR = 0.98 (95% CI 0.97–0.99). To improve the surveillance of future epidemics, new approaches are recommended.